Researcher Sonia Gavasso, PhD, with the Neuroimmunology Lab at Haukeland University Hospital in Bergen, Norway, recently chatted with Fluidigm about the role of mass cytometry in her team’s cancer research. Gavasso anticipates that mass cytometry, or cytometry by time-of-flight mass spectrometry (the technology used in the CyTOF® system), will help to align diagnostics with current biological understandings of cancer, noting that monitoring therapies is key to making better decisions.

Defining immunotherapy approaches

There’s always talk about the importance of developing personalized therapies in the clinic, but she believes there should also be personalized monitoring. Fueling her work at University of Bergen through self-described fascination and love of science, Gavasso explained, “I have a passion for biology and an imagination for complexity. When I moved to Norway and joined the Haukeland University Hospital, I began studying immunology and central nervous system diseases, which are highly complex. That’s where mass cytometry comes in.”

In the Expert Review of Molecular Diagnostics paper, “Single-cell proteomics: potential implications for cancer diagnostics,” Gavasso et al. issue an inspiring call for researchers to develop solutions addressing key problems in sustainable health care. “We believe new and emerging technologies will allow us to move from mostly empirical decisions to tailored treatments enabling fast and early decisions regarding response,” she said. “It would be the holy grail, even before treatment starts.”

In human medicine, it’s difficult to predict who will respond to an immunotherapy. The paper outlines an integral need for hands-on, simple technology to monitor response over time, rather than administering long-term treatment before differentiating between responders and nonresponders.

“Mass cytometry has amazing potential. I don’t want to use the word ‘revolutionize’, but it’s close to it. This is the first time we can clearly monitor the whole immune system for a really broad view of what’s going on and what we should do.”
—Sonia Gavasso, PhD, Neuroimmunology Lab, Haukeland University, Norway

Enter, Helios

Gavasso wanted to get a view of the immune system and how it behaves during therapy. “One out of three people die from cancer and it’s increasing, so something has to happen. There’s a real need for single-cell analysis technologies that revolutionize what we can do in research to translate into clinical diagnostics and monitoring. With CyTOF technology,” she continued, “we can go much deeper into whole system immunophenotyping to see where these medications actually work and where the antibody binds and has an effect. This is a completely new, holistic way to look at and monitor the immune system.”

When she heard about CyTOF technology in 2009, Gavasso remembered, some were skeptical, but she was thinking: “‘We should absolutely do this.’ I was fascinated and super excited about it.” She visited scientists in Paris who had a mass cytometer and recalled being amazed seeing it in action. “In Norway, they like established procedures and technologies so we had to wait a long time, but we didn’t give up.” Their Helios™ was a gift to the Haukeland University Hospital and University in Bergen funded through a Bergen Research Foundation grant.

“We now have a Helios system and it’s running really well. We have our own dedicated mass cytometry team here to take care of the system and run mass cytometry at the hospital where we collect lots of cells in clinical trials.” Gavasso holds great hopes for mass cytometry, citing around 20 major cryobanks collecting cell samples for mass cytometry applications in cancer, rheumatic, neurological and central nervous system diseases and advanced therapies like cryoimmunotherapy and stem cell transplantation. “We plan to get another Helios, and we look forward to being able to expand our mass cytometry capabilities with tissue imaging.”

Advantages over flow cytometry

The visualization in mass cytometry data is a major plus for Gavasso. “With mass cytometry, we’re finally getting a view of the elusive immune response in immune therapies. Disease systems are so complex. It’s super that we can look at a certain cell but not lose information about what other cell types are doing, or where they are within the immune system. That is absolutely unbelievable,” she said.

“Previously, this type of information was difficult to obtain in a single analysis with flow cytometry, and mass cytometry clearly expands our horizon,” she noted, “so we can monitor complexity.” Her team reported debulking in leukemia during kinase inhibitor treatment as early as seven days after starting. They also saw where a medicinal antibody binds and in which cell subtype. “It is unprecedented. We would not do this on the flow cytometer. There are too many tubes that are difficult to combine and need lots of controls.”

Gavasso gave the example of how medications come to the field after successful clinical trials, but how they actually work is often unknown, so researchers like her must rush to explain the mechanistic action. For her, mass cytometry is the technology to discover what immune-modulating compounds do in the immune system. “I am a believer,” she said. “Mass cytometry has amazing potential. I don’t want to use the word ‘revolutionize’, but it’s close to it. This is the first time we can clearly monitor the whole immune system for a really broad view of what’s going on and what we should do.”

Her lab in Bergen is currently running major Helios projects for which they’re collecting tissue and cell samples. For one study, they’re using Helios to monitor cryoimmunotherapy response in prostate cancer. Another involves developing stem cell transplant treatment approaches for MS and for leukemia using CyTOF technology to understand how the immune system reconstitutes after stem cell transplantation and immune ablation. The team is also studying graft versus host disease in cancer.

“Mass cytometry is not just equal to the methods they’ve been using, it’s actually much, much better.”
—Sonia Gavasso, PhD, Neuroimmunology Lab, Haukeland University, Norway

Papers in the pipeline

Gavasso has a proof-of-principle chronic myeloid leukemia (CML) study of treatment with nilotinib (Tasigna®), a tyrosine kinase inhibitor, in press. “We’d see clear changes three hours after initiating therapy and debulking after one week in this ENEST1 clinical trial substudy.” The team has the opportunity to collect samples before therapy and again within hours of treatment because they work closely with treating physicians in their clinical trial units. “In treatment,” Gavasso explained, “those early tests provide valuable information, so we don’t have to wait a whole year before we can label them responders or nonresponders.”

Ultimately, Gavasso dreams of being able to analyze immune cells in the brain in nervous system diseases. “It’s difficult to collect samples from within the central nervous system. And if we do get them,” she said, “it would be really cool to have excellent technologies for analyzing samples at any level from RNA to DNA to proteomics.”

Bioinformatics approach

Gavasso has several applications for working collaboratively with bioinformaticians to analyze biological, programming, algorithmic and statistical data from Helios, independent of what’s published. Her group works closely with lab mathematicians on topology, studying spatial properties preserved through stretching, crumpling, bending and twisting of objects to verify methodological usability.

Cytobank is a boon, especially for studying the clinical dataset needed to integrate with information from the mass cytometer. “CyTOF technology is better than how we did things before in the clinic, when we had to always select cells and parameters. This is really exciting,” she added. “Mathematicians here in Bergen actually come to us now asking for datasets.”

A new perspective

Mass cytometry for higher-parameter analysis of precious samples offers a number of advantages. “Personally, I was excited to let go of the two-dimensional flow cytometry approach,” she said. “Mass cytometry is amazing, but some people find change difficult and are reluctant to go high-dimension, saying, ‘We’ve been doing things this way forever. It works, so why change now?’” Gavasso’s answer: “Mass cytometry is not just equal to the methods they’ve been using, it’s actually much, much better.”

The C1™ system provides the widest range of automated single-cell applications in the industry, from gene expression profiling to genomic and epigenetic analysis. With more than 150 peer-reviewed publications, the C1 system has empowered significant research breakthroughs in the understanding of cell diversity and function in cancer, neurology, immunology and cardiovascular and stem cell biology.

The key to successful single-cell studies is preparing high-quality suspensions with maximum cell viability and minimum cell stress and debris. Whether you are working with cultured cells or with samples freshly isolated from tissue, cell quality is a critical factor for ensuring optimal results in single-cell datasets.

Now you can load enriched cell populations obtained by flow cytometric cell sorting directly into the C1 IFC (integrated fluidic circuit) to obtain rare subpopulations of cells with high purity and viability.

Benefits of this new application include:

To learn more, download the application note Cell Sorting Directly to the C1 IFC and the associated C1 cell sorting workbook today.

SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that leading research institutions in the UK have partnered to acquire and implement seven Helios™ mass cytometry systems to empower life-changing discoveries in human health. Supported by the Clinical Research Infrastructure Initiative (CRII) of the UK Medical Research Council (MRC), the MRC Consortium for Mass Cytometry includes researchers from the universities of Liverpool, Manchester, Newcastle, Cambridge, Birmingham and Oxford and University College London.

Helios utilizes CyTOF^® technology to enable deep profiling of translational and clinical research samples across a range of cell surface and intracellular markers by mass cytometry. Designed to significantly reduce signal overlap, mass cytometry empowers researchers to simultaneously interrogate cellular phenotypes, function and signaling status in higher dimension than traditional fluorescent methods. Mass cytometry is especially valuable in research studies when sample volumes are limited.

In support of the MRC Consortium for Mass Cytometry, Fluidigm sponsored the 2017 UK Mass Cytometry User Meeting, a two-day symposium held in London on March 21 and 22. This meeting brought together scientists from 19 major UK research centers to share recent research advances and best practices in mass cytometry.

"The Technology Directorate at Liverpool led the procurement and development of the MRC Consortium for Mass Cytometry in the UK," said Professor Robert Beynon, PhD, academic head of the Technology Directorate at the University of Liverpool. "By organizing the UK users meeting, Fluidigm is helping to make this vision, of pooled knowledge and shared infrastructure, a reality."

Symposium speakers included scientists from within the MRC consortium as well as mass cytometry users from other locations and technical specialists from Fluidigm. Topics included fundamentals of instrument operation and sample preparation, design of high-parameter biomarker panels, best practices for integrating mass cytometry into a core facility and cutting-edge research underway at several consortium locations.

"My favorite aspects of the meeting were being able to hear and discuss how the different groups associated with the consortium (and indeed other mass cytometry users outside the consortium) have developed and use the technology for different aspects of research, and also how they have adapted mass cytometry within their core service providers for wider use by their universities," said Joseph Slupsky, PhD, academic lead for the University of Liverpool Cell Sorting and Mass Cytometry Facility.

Dr. Slupsky's research is focused on chronic lymphocytic leukemia (CLL). "I am using mass cytometry to measure phenotypic changes, signal transduction and gene expression within distinct subpopulations of CLL cells," Dr. Slupsky said. "Mass cytometry will also be used to understand patient response to drug therapy in this disease and gain insight into the mechanisms of drug toxicity and efficacy."

"We are enthusiastic about the collective power of the MRC Consortium for Mass Cytometry to achieve new breakthroughs in an environment of shared infrastructure and best practices," said Chris Linthwaite, President and CEO of Fluidigm. "The great progress these institutions have made since the successful installation of these seven systems was evident at our recent UK user meeting."

About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm, the Fluidigm logo, CyTOF, and Helios are trademarks or registered trademarks of Fluidigm Corporation.

Next-generation sequencing (NGS) has been instrumental in advancing the understanding of human health and disease. Growing demand for sequencing around the world is driving the need for workflow improvements and cost efficiencies.

Enter Juno™, the industry’s only fully programmed benchtop nanofluidics system, built to scale genomics workflows to optimum efficiency. The platform’s newest commercial application is targeted DNA sequencing library prep, which includes everything needed to prepare NGS-ready libraries including integrated custom assay design services.

High capacity

Juno library prep is optimized for use with Illumina® sequencing systems, bringing new sequencing efficiencies to labs running targeted NGS assays on the mid- to high-throughput scale. With processing capacity of up to 192 samples per run, sample throughput is at least twice that of other systems available today. One operator with a single Juno instrument can prepare up to 1,536 NGS-ready targeted DNA libraries weekly. For labs processing smaller batch sizes, Juno provides the same benefits of expedient turnaround time and walkaway workflow, yielding highly consistent NGS-ready amplicon libraries.

Flexibility

Juno library prep chemistry enables a range of assay panel options. You can amplify up to 4,800 amplicons per sample, access expert design services and ready-to-use primer delivery. Plus, the ability to add amplicon assays over time ensures your panel content stays up to date. Additionally, Juno targeted DNA library prep for NGS can operate overnight without monitoring, maximizing productivity over 24 hours.

“We are pleased to announce the Juno Targeted DNA Sequencing Library Preparation System as an expansion of our growing portfolio of automated genomic workflows that increase laboratory efficiency for medium-to-high-throughput pipelines,” said Steve McPhail, General Manager of Clinical and Applied Markets at Fluidigm. “We are now able to offer our customers a significant improvement over the largely manual, low-throughput and laborious NGS library preparation workflows used today.”

Learn more about new Juno Targeted DNA Sequencing Reagents.